Table 2.
EE, RQ, and Spontaneous Physical Activity After Placebo and RM-493 Administration in Obese Individuals
| RM-493 | Placebo | P | |
|---|---|---|---|
| REEC (kcal/d) | 1856 ± 369 | 1745 ± 359 | .028 |
| REEH (kcal/d) | 1849 ± 388 | 1769 ± 379 | .059 |
| TEE (kcal/d) | 2509 ± 420 | 2457 ± 399 | .089 |
| Components of TEE | |||
| SEE (kcal/m) | 1.35 ± 0.19 | 1.35 ± 0.18 | .938 |
| Exercise EE (kcal/m)a | 4.49 ± 0.96 | 4.49 ± 1.05 | .998 |
| TEF (kcal/m) | 1.81 ± 0.31 | 1.76 ± 0.33 | .145 |
| 23-hour RQb | 0.83 ± 0.02 | 0.85 ± 0.02 | .017 |
| Spontaneous physical activity | |||
| Hip counts/min | 304 ± 108 | 325 ± 85 | .300 |
| Wrist counts/min | 1307 ± 335 | 1245 ± 465 | .434 |
| Steps/min | 3.22 ± 1.32 | 3.51 ± 1.10 | .333 |
| % sedentary time | 80.7 ± 4.9 | 80.7 ± 4.6 | .940 |
Posttreatment values shown are unadjusted means ± SD. Posttreatment values were adjusted for baseline value and treatment group using a mixed-model regression. P values indicate significance for comparisons between RM-493 and placebo.
a
n = 10, 2 patients were excluded from analysis because of markedly different exercise efforts during the 2 phases.
b
Averaged RQ over all nonexercise periods in the chamber.